Table 2.
Baseline levels of N‐acetyl aspartate (NAA), choline compounds (Cho) and creatine in bipolar subjects and healthy volunteers, and changes in the same 1H‐MRS metabolite levels in bipolar subjects who completed the 16‐week treatment (Institutional Units, mean ± SD)
| Metabolite | Hippocampus | Bipolar subjects (N = 18) | Healthy volunteers (N = 10) | Statistics | Bipolar completers—baseline (N = 8) | Bipolar completers—endpoint (N = 8) | Statistics |
|---|---|---|---|---|---|---|---|
| NAA | Left | 5.26 ± 3.63 | 3.32 ± 3.68 | df = 26, t= 1.35, P= 0.19 | 4.87 ± 1.78 | 8.15 ± 4.74 | df = 7, t= 2.63, P= 0.039* |
| Right | 6.41 ± 2.11 | 4.44 ± 2.01 | df = 26, t= 2.38, P= 0.025* | 6.11 ± 1.49 | 5.38 ± 2.72 | df = 7, t= 1.37, P= 0.21 | |
| Cho | Left | 2.12 ± 1.08 | 0.90 ± 0.96 | df = 26, t= 2.99, P= 0.006* | 2.41 ± 0.93 | 1.30 ± 0.84 | df = 7, t= 2.52, P= 0.040* |
| Right | 1.88 ± 0.66 | 1.24 ± 0.50 | df = 25, t= 2.66, P= 0.014* | 1.88 ± 0.62 | 1.48 ± 0.67 | df = 7, t= 0.94, P= 0.38 | |
| Creatine | Left | 5.71 ± 2.90 | 2.97 ± 2.99 | df = 26, t= 2.36, P= 0.026* | 6.17 ± 3.16 | 6.04 ± 3.45 | df = 7, t= 0.49, P= 0.64 |
| Right | 5.16 ± 1.86 | 3.58 ± 1.48 | df = 26, t= 2.29, P= 0.031* | 5.90 ± 2.00 | 4.76 ± 2.03 | df = 7, t= 0.89, P= 0.40 |
*P < 0.05.